The FDA approved 2 companies to begin manufacturing generic Eliquis: Micro Labs and Mylan Pharmaceuticals yesterday. It’s all over news wires. I would think it would be on shelves before 2023
Pfizer has a division called Upjohn which has joined forces with Mylan and is/will be selling Pfizer's generics.
Late 2025. Generic approvals are just noise in the system at this point. Generic companies have nothing to lose filing for these approvals.
Three Eliquis patents expired on Dec 22, 219. Generic will hit shelves in 2-3 months. Eliquis/chantix group may dissolve. Many reps have and support staff have moved to other divisions. In 2024, Pfizer will have little to no sales force.
The last patent expires Feb 2023. Figure the end of promotion end of year 2022. Christmas reorg and layoffs. Internal medicine is running out of drugs to promote.
2023/24. It will be challenged next year and 2021 or 2021 some early entry agreement will be made w Teva to have narrow indication & profit sharing 2 yrs early to the market-- much same way Lipitor was done. Same will happen to Xeljanz. That is $4 Billion a yr in sales from 2 blockbusters going generic 2024 timeframe with likely early entry contract agreements in 2022 range. I&I has BioSimilar Humira to replace Xeljanz but what does Cluster IM have to replace Eliquis- Tanuza????
